InvestorsHub Logo
Followers 0
Posts 204
Boards Moderated 0
Alias Born 03/29/2019

Re: None

Tuesday, 03/24/2020 9:00:33 AM

Tuesday, March 24, 2020 9:00:33 AM

Post# of 43769
We are getting a lot of press in the last couple of days.

Ted Ross says....

"LEAPS has the potential to be a powerful tool against SARS-CoV-2, the causative agent of COVID-19, based on its dual anti-viral and anti-inflammatory properties. Combining the prior pre-clinical data of LEAPS against H1N1 with our advancing knowledge of COVID-19, we aim to rapidly evaluate this technology’s potential to meet the urgent need to treat patients at greatest risk of dying from this global pandemic. The University of Georgia’s biocontainment labs at the Center for Vaccines and Immunology are ideally suited for these studies, and will serve as critical assets in this collaboration with CEL-SCI.”

Ted M. Ross, Ph.D., Director of the Center for Vaccines and Immunology, Georgia Research Alliance Eminent Scholar, and Professor of Infectious Diseases at the University of Georgia
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News